HIT Consultant has published an article on BERG Analytics multi-year commercial agreement with Becton Dickinson to apply our AI platform bAIcis™ in order to provide deep analysis of the BD/MedMined hospital data with the objective of discovering new patterns and risk factors of patient medication non-compliance. The full article can be viewed here: http://hitconsultant.net/2017/01/12/bd-berg-health-partnership/

In the Economist, our CEO Niven R. Narain explains how BERG uses artificial intelligence to analyze tissue samples and clinical data to model and understand diseases and guide drug discovery. Learn more in the latest Economist issue: http://www.economist.com/news/science-and-technology/21713828-silicon-valley-has-squidgy-worlds-biology-and-disease-its-sights-will

Op ed in Drug Discovery & Development by Niven R Narain on the need to use technology to disrupt the current industry model of drug development. Full article can be viewed here: An industry overdue for disruption

Employees, colleagues, family and friends of BERG will be participating in Purplestride Boston 2016  to raise awareness and funds for pancreatic cancer research.  This is BERG’s second year participating in the event along with our Project SurvivalSM partners at the Beth Israel Deaconess Medical Center.  Project Survival’sSM mission is to discover and validate the first-ever…

Tech.co talks to Niven Narain about how BERG is aiming to reduce the costs associated with developing treatments by utilizing patient biology and artificial intelligence. You can listen to the podcast here: https://podcasts.apple.com/gb/podcast/ai-patient-biology-accelerating-transform-drug-discovery/id1018727913?i=1000502752435

Liz Harley of Frontline Genomics sits down with BERG’s CEO Niven R. Narain to discuss AACR and our approach to taking on cancer.